PacBio (PACB) and Intus Bio unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay and AI-powered analysis with PacBio’s renowned sequencing accuracy, GutID sets a new benchmark in gut microbiome testing, and is the only comprehensive and accurate gut microbiome test available. Offering the highest resolution analysis possible, GutID is a major breakthrough as it delivers robust and repeatable results, which can be used with confidence to help understand and manage the microbiome, a known critical driver of health outcomes including cancer.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio announces shipment of Vega systems to Berry Genomics
- Unusually active option classes on open January 7th
- Cathie Wood’s ARK Investment bought 397K shares of PacBio today
- Cathie Wood’s ARK Investment buys 341K shares of PacBio today
- Cathie Wood’s ARK Investment buys 274.9K shares of PacBio today